Research Articles - Retinitis Pigmentosa
At the Foundation’s meeting of Translational Research Acceleration Program (TRAP) investigators in Las Vegas earlier this week, Al Lewin, Ph.D., of the University of Florida, discussed progress in tackling the vexing problem of developing gene therapies for autosomal dominant retinal disease — specifically retinitis pigmentosa (RP) caused by mutations in the gene rhodopsin (RHO). His team’s project is funded through
A drug developed by the company QLT for the treatment of retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) caused by mutations in the genes RPE65 or LRAT restored visual acuity or visual field in 11 of 14 patients in a Phase 1B clinical trial. Vision improvements for a seven-day course of the drug were sustained for two years for some study participants. No serious adverse events
- Thanks to success in preclinical studies funded in part by the Foundation Fighting Blindness, the Irish biopharmaceutical company Genable Technologies has received a €5 million (equivalent to about $6.8 million) venture capital investment to advance its gene therapy for autosomal dominant retinitis pigmentosa (adRP) into a clinical trial.
A Foundation-funded investigative team led by Ruifang Sui, M.D., Ph.D., of Peking Union Medical College Hospital, has completed the first comprehensive genetic screening of a group of Chinese people with autosomal recessive retinitis pigmentosa (arRP). Results of the
The Argus II® Retinal Prosthesis System, which restores some useful vision to people blind from advanced retinitis pigmentosa, will be offered later this year at 12 clinical centers throughout the United States.
The Argus II retinal prosthesis, a device that can restore some vision to people who are blind from advanced retinitis pigmentosa (RP), has received U.S. market approval from theFood and Drug Administration (FDA). Developed by Second Sight Medical Products, the device will be available later this year in approximately 10 clinical centers across the country. In 2011, the Argus II received marketing approval in Europe. Also known as a “bionic retina,” it is currently the world’s only retinal
The Alpha IMS, a subretinal implant developed by Retina Implant AG of Reutlingen, Germany, has been granted European marketing approval. The device received a CE Mark, a regulatory designation for meeting European safety and reliability standards. Also known as an artificial or bionic retina, the Alpha IMS has
An artificial retina developed by Retina Implant AG of Reutlingen, Germany, has restored meaningful vision to most of the nine blind people — eight with retinitis pigmentosa, one with cone-rod dystrophy — enrolled in a clinical trial. Five of the participants recognized objects such as door knobs, telephones and facial features. One person was able to read store and restaurant signs, and another was able to observe the movements of a wild goose.
Interim results of the clinical trial were published online in
The development program for a new drug with the potential to treat a common form of autosomal dominant retinitis pigmentosa (adRP) has received a boost with Shire’s acquisition of BIKAM Pharmaceuticals, the original developer of the experimental treatment.
The Foundation Fighting Blindness Clinical Research Institute (FFB CRI) has completed patient enrollment for its Phase II clinical trial for valproic acid, a therapy which has shown some suggestion of slowing loss of visual function in people with autosomal dominant retinitis pigmentosa (adRP). Valproic acid was previously approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizure disorders. The 90-participant study of valproic acid for people with confirmed adRP was